Drug Therapy Protocols: Ketamine

<table>
<thead>
<tr>
<th>Policy code</th>
<th>DTP_KET_0519</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td>May, 2019</td>
</tr>
<tr>
<td>Purpose</td>
<td>To ensure a consistent procedural approach to ketamine administration.</td>
</tr>
<tr>
<td>Scope</td>
<td>Applies to all Queensland Ambulance Service (QAS) clinical staff.</td>
</tr>
<tr>
<td>Health care setting</td>
<td>Pre-hospital assessment and treatment.</td>
</tr>
<tr>
<td>Population</td>
<td>Applies to all ages unless specifically mentioned.</td>
</tr>
<tr>
<td>Source of funding</td>
<td>Internal – 100%</td>
</tr>
<tr>
<td>Author</td>
<td>Clinical Quality &amp; Patient Safety Unit, QAS</td>
</tr>
<tr>
<td>Review date</td>
<td>May, 2022</td>
</tr>
</tbody>
</table>

While effort has been made to contact all copyright owners this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: Clinical.Guidelines@ambulance.qld.gov.au

Disclaimer

The Digital Clinical Practice Manual is expressly intended for use by QAS paramedics when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.


This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en](http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en)

For copyright permissions beyond the scope of this license please contact: Clinical.Guidelines@ambulance.qld.gov.au
**Ketamine**

**Drug class**
- Anaesthetic
- Analgesic

**Pharmacology**
Ketamine is an anaesthetic agent that acts as a NMDA receptor antagonist. At lower doses this drug produces significant analgesia, whilst the airway reflexes and respiratory drive are preserved. At higher doses ketamine can be used as an induction agent for anaesthesia. Unlike other general anaesthetics, there is minimal haemodynamic compromise as ketamine acts as a sympathomimetic agent. However this may result in potentially transient tachycardia and hypertension. Ketamine produces a dissociative state and this will cause the patient to potentially have significant issues with perception, resulting in disinhibition or emergence phenomenon.[1–4]

**Metabolism**
Ketamine undergoes extensive hepatic metabolism with approximately 90% of the drug excreted in the urine as metabolites.[8]

---

**Indications**

- **Severe traumatic pain** (following 0.1–0.2 mg/kg morphine OR 1–2 microg/kg fentanyl) associated with:
  - fracture reduction and splinting
  - multiple or significant fractures requiring facilitated extrication
  - patients with splinted fractures requiring ongoing narcotic analgesia for transport requirements

---

**Indications (cont.)**

- Severe traumatic pain associated with burns (following 0.2–0.3 mg/kg morphine OR 2–3 microg/kg fentanyl AND 1–2 mg (adult) or 0.05 microg/kg (paediatric) midazolam)
- Induction of anaesthesia
- Ongoing traumatic pain unresponsive to narcotics (following 0.2–0.3 mg/kg morphine OR 2–3 microg/kg fentanyl)
- Acute behavioural disturbance (with a SAT score of ≥ 2) unresponsive to droperidol (max dose) administration

---

**Contraindications**

- Analgesia
  - Allergy and/or Adverse Drug Reaction
  - Age < 1 years
  - GCS ≤ 12
  - Uncontrolled hypertension (SBP ≥ 180 mmHg AND/OR DBP ≥ 110 mmHg)
  - Suspected ACS or acute heart failure
  - Known hydrocephalus or raised intra-ocular pressure
- Induction of anaesthesia
  - Allergy and/or Adverse Drug Reaction
**Ketamine**

**Precautions**
- Age > 65 years
- Patients who have been administered midazolam or other CNS depressant medication
- Patients with significant hypovolaemia (exaggerated effects and a delayed onset of action)
- Globe injuries
- Complex facial injuries and fractures
- Patients who have impaired respiratory function
- Patients exhibiting psychotic symptoms

**Side effects**
- Dissociation and trance-like state
- Transient hypertonicity and nystagmus
- Disinhibition
- Emergence
- Hypertension
- Tachycardia
- Depression of consciousness
- Hypersalivation
- Nausea and/or vomiting
- Laryngospasm
- Respiratory depression (rare)

**Presentation**
- Ampoule, 200 mg/2 mL *ketamine hydrochloride*

**Onset (IV) | Duration (IV) | Half-life**
---|---|---
30 seconds | 5–20 minutes | 10–15 minutes

**Schedule**
- S8 (Controlled drugs).

**Routes of administration**
- Intramuscular injection (IM)
- Intravenous injection (IV)
- Intraosseous injection (IO)
**Special notes**

- Ambulance officers must only administer medications for the listed indications and dosing range. Any consideration for treatment outside the listed scope of practice requires mandatory approval via the QAS Clinical Consult and Advice Line.

- When applicable, paramedics are to adhere to all the requirements of *CPG: Sedation – procedural*, including the application of nasal EtCO₂ measurement where practical.

- Transient hypertension and tachycardia may occur following ketamine administration in some patients. Unless the hypertension or tachycardia is profound and/or sustained, ketamine administration may continue. For all borderline cases CCPs are to discuss with the QAS Clinical Consultation and Advice Line prior to administration.

- Midazolam is not to be administered unless the patient displays significant signs of emergence that are not attenuated with reassurance.

- Once the maximum analgesia dose of 1 mg/kg is administered, the QAS Clinical Consultation and Advice Line must be consulted prior to any further ketamine being administered.

- All parenteral medications must be prepared in an aseptic manner. The rubber stopper of all vials must be disinfected with a 2% Chlorhexidine/70% Isopropyl Alcohol swab and allowed to dry prior to piercing.

**Adult dosages**

- **Severe traumatic pain** (following 0.1–0.2 mg/kg morphine OR 1–2 microg/kg fentanyl) associated with:
  - Fracture reduction and splinting
  - Multiple or significant fractures requiring facilitated extrication
  - Patients with splinted fractures requiring ongoing narcotic analgesia for transport requirements

- **Ongoing traumatic pain unresponsive to narcotics** (following 0.2–0.3 mg/kg morphine OR 2–3 microg/kg fentanyl)

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
<th>Repeat</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV</td>
<td>10–30 mg</td>
<td>Every 2–3 minutes</td>
<td>1 mg/kg</td>
</tr>
</tbody>
</table>

**Syringe preparation:** Mix 200 mg (2 mL) of ketamine with 18 mL sodium chloride 0.9% OR water for injection in a 20 mL syringe to achieve a concentration of 10 mg/mL. Ensure all syringes are appropriately labelled.

**Severe traumatic pain associated with burns** (following 0.2–0.3 mg/kg morphine OR 2–3 microg/kg fentanyl AND 1–2 mg midazolam)

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
<th>Repeat</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV</td>
<td>10–30 mg</td>
<td>Every 2–3 minutes</td>
<td>1 mg/kg</td>
</tr>
</tbody>
</table>

**Syringe preparation:** Mix 200 mg (2 mL) of ketamine with 18 mL sodium chloride 0.9% OR water for injection in a 20 mL syringe to achieve a concentration of 10 mg/mL. Ensure all syringes are appropriately labelled.
**Paediatric dosages**

**Severe traumatic pain** (following 0.1 – 0.2 mg/kg morphine OR 1 – 2 microg/kg fentanyl) associated with:
- Fracture reduction and splinting
- Multiple or significant fractures requiring facilitated extrication
- Patients with splinted fractures requiring ongoing narcotic analgesia for transport requirements

<table>
<thead>
<tr>
<th>Method</th>
<th>Age</th>
<th>Dosage</th>
<th>Repeat</th>
<th>Total Maximum Dose</th>
<th>Syringe Preparation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IV</strong></td>
<td>&gt; 1 year</td>
<td>0.1 – 0.3 mg/kg</td>
<td>&gt; 2 – 3 minutes</td>
<td>1 mg/kg</td>
<td>Mix 200 mg (2 mL) of ketamine with 18 mL sodium chloride 0.9% OR water for injection in a 20 mL syringe to achieve a final concentration of 10 mg/mL. Decant 18 mL of the prepared solution and dilute with a further 18 mL of sodium chloride 0.9% in a 20 mL syringe to achieve a final concentration of 1 mg/mL. Ensure all syringes are appropriately labelled.</td>
</tr>
</tbody>
</table>

**Severe traumatic pain associated with burns** (following 0.2 – 0.3 mg/kg morphine OR 2 – 3 microg/kg fentanyl AND 0.05 mg/kg midazolam)

<table>
<thead>
<tr>
<th>Method</th>
<th>Age</th>
<th>Dosage</th>
<th>Repeat</th>
<th>Total Maximum Dose</th>
<th>Syringe Preparation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IV</strong></td>
<td>&gt; 1 year</td>
<td>0.1 – 0.3 mg/kg</td>
<td>&gt; 2 – 3 minutes</td>
<td>1 mg/kg</td>
<td>Mix 200 mg (2 mL) of ketamine with 18 mL sodium chloride 0.9% OR water for injection in a 20 mL syringe to achieve a final concentration of 10 mg/mL. Decant 18 mL of the prepared solution and dilute with a further 18 mL of sodium chloride 0.9% in a 20 mL syringe to achieve a final concentration of 1 mg/mL. Ensure all syringes are appropriately labelled.</td>
</tr>
</tbody>
</table>

**Acute behavioural disturbance** (with a SAT score of ≥ 2) unresponsive to droperidol (max dose) administration

<table>
<thead>
<tr>
<th>Method</th>
<th>Age</th>
<th>Dosage</th>
<th>Repeat</th>
<th>Total Maximum Dose</th>
<th>Syringe Preparation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IM</strong></td>
<td>≥ 16 years</td>
<td>200 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Paediatric dosages (cont.)

### Induction for anaesthesia

| IV | QAS Clinical Consultation and Advice Line approval required in all situations. **0.25–2 mg/kg** Single dose only **Total maximum dose 100 mg.**  
**Syringe preparation:** Mix 200 mg (2 mL) of ketamine with 18 mL sodium chloride 0.9% OR water for injection in a 20 mL syringe to achieve a final concentration of 10 mg/mL. Ensure all syringes are appropriately labelled. |
|---|---|
| IO | QAS Clinical Consultation and Advice Line approval required in all situations. **0.25–2 mg/kg** Single dose only **Total maximum dose 100 mg.**  
**Syringe preparation:** Mix 200 mg (2 mL) of ketamine with 18 mL sodium chloride 0.9% OR water for injection in a 20 mL syringe to achieve a final concentration of 10 mg/mL. Ensure all syringes are appropriately labelled. |